During the last session, Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s traded shares were 1.12 million, with the beta value of the company hitting 0.38. At the end of the trading day, the stock’s price was $6.42, reflecting an intraday gain of 0.47% or $0.03. The 52-week high for the PHAT share is $19.71, that puts it down -207.01 from that peak though still a striking 36.6% gain since the share price plummeted to a 52-week low of $4.07. The company’s market capitalization is $447.07M, and the average intraday trading volume over the past 10 days was 1.42 million shares, and the average trade volume was 1.12 million shares over the past three months.
Phathom Pharmaceuticals Inc (PHAT) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.25. PHAT has a Sell rating from 2 analyst(s) out of 10 analysts who have looked at this stock. 2 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -1.06.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information
Phathom Pharmaceuticals Inc (PHAT) registered a 0.47% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.47% in intraday trading to $6.42, hitting a weekly high. The stock’s 5-day price performance is 5.59%, and it has moved by 15.05% in 30 days. Based on these gigs, the overall price performance for the year is -41.74%. The short interest in Phathom Pharmaceuticals Inc (NASDAQ:PHAT) is 14.36 million shares and it means that shorts have 11.78 day(s) to cover.
The consensus price target of analysts on Wall Street is $18, which implies an increase of 64.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $18 and $18 respectively. As a result, PHAT is trading at a discount of -180.37% off the target high and -180.37% off the low.
Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts
In the rating firms’ projections, revenue will increase 196.23% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 27.91M as predicted by 8 analyst(s). Meanwhile, a consensus of 8 analyst(s) estimates revenue growth to 37.2M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 1.91M and 7.32M respectively. In this case, analysts expect current quarter sales to grow by 1,359.83% and then jump by 407.88% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 12.50%. While earnings are projected to return 24.15% in 2025.
PHAT Dividends
Phathom Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-Mar-05. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT)’s Major holders
Phathom Pharmaceuticals Inc insiders own 3.80% of total outstanding shares while institutional holders control 97.01%, with the float percentage being 100.84%. FRAZIER LIFE SCIENCES MANAGEMENT, L.P. is the largest shareholder of the company, while 205.0 institutions own stock in it. As of 2024-06-30, the company held over 10.11 million shares (or 17.2637% of all shares), a total value of $104.13 million in shares.
The next largest institutional holding, with 7.46 million shares, is of MEDICXI VENTURES MANAGEMENT (JERSEY) LTD’s that is approximately 12.7473% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $76.89 million.
Also, the Mutual Funds coming in first place with the largest holdings of Phathom Pharmaceuticals Inc (PHAT) shares are Invesco Global Fund and PGIM Jennison Health Sciences Fund . Data provided on Oct 31, 2024 indicates that Invesco Global Fund owns about 1.98 shares. This amounts to just over 2.84 percent of the company’s overall shares, with a $12.68 million market value. The same data shows that the other fund manager holds slightly less at 1.78, or about 2.56% of the stock, which is worth about $11.44 million.
